Concepedia

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Liselore Loverix, Ignace Vergote, Pieter Busschaert, Adriaan Vanderstichele, Tom Venken, Bram Boeckx, Philipp Harter, Hilde Brems, Els Van Nieuwenhuysen, Sandro Pignata,

European Journal of Cancer · 2023 · 37 citations · 17 references

DOI

Concepts

References

17

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

, , +17

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text

, , +15

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · New England Journal of Medicine · 2019 · 2K citations · Full text

, , +14

Allele-specific copy number analysis of tumors

Peter Van Loo, Ole Christian Lingjærde, Hege G. Russnes et al. · Proceedings of the National Academy of Sciences · 2010 · 1.3K citations · Full text

, , +17

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Melinda L. Telli, Kirsten M. Timms, Julia Reid et al. · Clinical Cancer Research · 2016 · 1.2K citations · Full text

, , +17